Molecular Imaging in Drug Development


MNI provides unsurpassed experience and depth of knowledge in in vivo pharmacokinetic and target occupancy studies critical to the rapid development of novel therapeutic drugs.

Our medicinal chemistry facility develops radioligands, precursor and reference standard, for novel targets or makes improvements to existing radioligands. Once suitable candidates have been radio-labeled they are tested in vitro and the following parameters are evaluated in vivo:

  • Measure tracer pharmacokinetics and metabolic profile
  • Dosimetry studies
  • Blockade studies with reference compound to evaluate specificity
  • Dose occupancy studies of drug candidate